PANEL 04 // THE DOSE-CONTEXT RECORD
BPC-157 TB-500 dosage, as studied — not as prescribed
Animal-model dose ranges per body weight, the routes the research actually used, and a flat statement of why no validated blend dose exists.
Research dosing context for the BPC-157 / TB-500 blend
BPC-157 TB-500 dosage has no validated value for the blend. The figures below come from single-compound animal studies and describe what was administered to which species by which route — they are not human guidance and do not translate to a blend dose. The framing throughout this panel is deliberate: "studied at X in [species] by [route]," never "take X."
The BPC-157 channel, in rodent models, is commonly expressed per body weight, frequently around 10 microg/kg and 10 ng/kg [1]. Expressing a dose per kilogram of body weight is how animal pharmacology works, and it is precisely why those numbers cannot be lifted into a fixed human milligram amount. The TB-500 / Thymosin Beta-4 channel spans a far wider range in the underlying studies — for example a rat embolic-stroke dose-response study used 2-18 mg/kg intraperitoneal, with the highest dose giving no benefit (higher was not better), and a six-month mdx muscular-dystrophy study used 150 microg twice weekly intraperitoneally [4]. That non-monotonic result is the single most useful caution on this page, because it directly contradicts the loading logic behind many community blend protocols.
Human single-agent reference points exist only for full-length Thymosin Beta-4, not the blend: intravenous Thymosin Beta-4 was well tolerated in Phase 1 work [4]. Commercial vials commonly pair fixed combined masses (e.g. ~10 mg + ~10 mg), but no peer-reviewed combination dose-finding study exists, and the fixed-mass label is a packaging convention, not a validated dose [1].
How do you cycle BPC-157 and TB-500?
There is no validated cycle for the blend. Community "loading then maintenance" protocols and fixed-ratio vials (e.g. 10 mg + 10 mg) have no basis in controlled human trials; the underlying studies are animal models dosed per body weight, and one stroke study found dosing non-monotonic — higher was not better [4].
Routes studied for the Wolverine blend constituents
The routes the research used are not the routes the community uses, and the distinction matters for anyone reading vendor protocols or searching for a "wolverine injection" schedule. The underlying rodent efficacy studies for both peptides were predominantly intraperitoneal; human Phase 1 data for full-length Thymosin Beta-4 used intravenous routes [4]. Subcutaneous and intramuscular administration are the predominant research-community routes for the blend, but they do not come from controlled human efficacy trials. There is no validated injection frequency for the blend; the rodent studies dosed on study-specific schedules — for example 150 microg twice weekly in one six-month mouse study [4].
Oral versus injectable handling in the literature
BPC-157 is studied as a stable gastric peptide, so oral routes appear in its individual-compound literature [1]. Blend oral products are marketed but lack validated pharmacokinetics. The rodent efficacy studies for both peptides were predominantly injected (intraperitoneal), so oral blend bioavailability is not established by controlled data.
What is the half-life of BPC-157 and TB-500?
No validated human PK half-life exists for either constituent at research-use doses, and none for the blend. BPC-157's elimination half-life was reported under 30 minutes in a rat/dog study; human full-length Thymosin Beta-4 showed dose-proportional PK, but no specific half-life is established for the TB-500 heptapeptide [4].
How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated. In unregulated "Wolverine" material the actual BPC-157:TB-500 ratio, identity, and purity are not guaranteed, so no validated reconstitution figure can be stated for the blend [1][5].
